Board of Directors

Portrait_JohnKeith

Non-Executive Chairman

John Keith

John is the Managing Director of BNP Paribas. Prior to that, he led management and coverage roles for Nomura Securities in Sydney and Hong Kong. John also serves as a Director of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation.

Portrait_JohnKelly

Founder, Managing Director & CEO

John Kelly

For more than 20 years John Kelly has championed the cause of reimagining medical devices to enhance their usability and performance. Before founding Atomo Diagnostics in 2010, John was Chief Operating Officer at ASX listed (now NASDAQ listed) Unilife Corporation, where he led the ‘Unifill’ development team to develop the world’s first glass prefilled drug delivery device with integrated auto retract safety feature.  This technology was successfully licensed to Sanofi Aventis.  Previously, John led the New Product Implementation Group at ResMed, where he managed the design and commercialisation of the ground-breaking Mirage Swift mask. In addition to his commercial experience, John has an Honours Degree in Mechanical Engineering from the University of Liverpool, a Master’s Degree in Systems Engineering from Queen’s University Belfast, and an Executive MBA from the University of Sydney, where he was awarded the Business School’s inaugural ‘Excellence in Leadership’ scholarship.

curt-labelle-e1483909245989

Non-Executive Director

Dr Curt LaBelle

Dr LaBelle has been actively involved in the healthcare industry for 20 years, both operationally and as an investor. He is the Managing Partner at the Global Health Investment Fund, a social impact investment fund, which manages approximately US$108 million backed by the Gates Foundation, JP Morgan and others. He also serves as a director on the boards of Alydia Health, Atticus Medical and Eyenovia.  Prior to joining GHIF, Dr LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital. He also served as chairman on the boards of Exagen Inc. (NASDAQ:XGN) and Impulse Monitoring (acquired by Nuvasive) and as a director on the boards of Sirion Therapeutics, SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen).

Connie-Carnabuci

Non-Executive Director

Connie Carnabuci

General Counsel of the Australian Broadcasting Corporation. Non-executive director of OFX Group Limited(ASX:OFX). 30 years’ experience advising intellectual property and technology intensive businesses in Australia and across Asia. Connie is a former partner of Mallesons Stephen Jacques and Freshfields Bruckhaus Deringer. Member of the Business Advisory Council of the UNSW Business School. Vice President of the Cranbrook School Parents Association. She was the Chair of the NFP, Kids Giving Back, from 2015 to 2018.

Dr-Paul-Kasian

Non-Executive Director

Dr Paul Kasian

Chairman of IODM Limited. Non-executive Director of Eco Systems Ltd (ASX:ESL). Previously Chairman and CEO of Genetic Technologies Limited. PhD in Microbiology and MBA, both from the University of Melbourne, and GAICD. Former Chief Investment Officer and Head of Global Financials at HSBC Asset Management; Founding Director of Accordius; Founding Director of Wallara Asset Management.

Partner with Atomo Diagnostics for best-in-class lateral flow testing.

Atomo-Diagnostics-Award-Logo-150x150